Abstract: The present invention provides ketoreductase variants having activity on both (R)-(?)-1,3-butanediol and (S)-(+)-1,3-butanediol, and the computational methodology for designing the above mentioned ketoreductase variants. The ketoreductase variants disclosed in the present application can catalyze the reaction of synthesizing 4-hydroxy-2-butanone from racemic 1,3-butanediol, which has industrial application prospects.

Abstract: Provided are a battery cabinet including a cabinet body and a drain valve assembly. The bottom of the drain valve assembly is fixed, by an installation port at the bottom of the cabinet body, to the battery cabinet from bottom to top, and the top of the drain valve assembly is in butt joint with a drain outlet in the cabinet body. The drain valve assembly is provided with magnetic substances, which can realize automatic drainage. Compared with a method for installing a drain valve assembly from the inside of a battery cabinet in the prior art, the operation of fixing the drain valve assembly through the installation port in the present application is more convenient, the drain valve assembly can be disassembled without moving battery cells in the cabinet, and thus convenience of disassembly and assembly of the drain valve assembly is improved.

Abstract: The present application relates to a supercritical fluid injection foaming polylactide foam material and a preparation method therefor. The method includes: first obtaining a surface-modified cellulose nanofiber aqueous solution; then melting and blending the cellulose nanofiber aqueous solution and a polylactide twice; passing same through extrusion, cooling under water, and granulation so as to obtain a polylactide/cellulose nanofiber composite material; then plasticizing and melting the polylactide/cellulose nanofiber composite material in a microporous foaming injection molding machine; uniformly mixing same with a supercritical fluid foaming agent in the injection molding machine; injecting same into a mold cavity; and subjecting the resultant to post-treatment so as to obtain a polylactide foam material.

Abstract: An electronic device is connected to a master headset and a slave headset. The master headset performs talk right arbitration. A voice automatically picked up by a headset having a talk right may be uploaded to the electronic device. The electronic device translates the uploaded voice, and then returns a translation result.

Abstract: A method and device for rapid shopping are applicable to the field of an internet of things. The method includes: touching an NFC label and reading data content of the NFC label by a smart terminal (S101); parsing the data content of the NFC label and initiating a shopping scene according to a parsing result by the smart terminal (S102); and receiving a shopping selection and processing a shopping order according to a final result of the shopping selection by the smart terminal (S103). The method rapidly initiates a shopping scene and completes shopping of related commodity by means of a smart terminal.

Abstract: Disclosed are an N-substituted pyrazolo [3,4-d] pyrimidine ketone compound of formula (I), and a preparation process and use thereof as a phosphodiesterase IX (PDEIX) inhibitor: wherein R? is selected from isopropyl, cyclopentyl, cyclohexyl, isobutyl, and o-chlorophenyl; when R??CH3, R represents benzyl; and when R??H, R is selected from 3-methylpyridine, 1-phenylethyl, 1-(4-chlorophenyl)ethyl, D- or L-configured CHCH3CONHR??, D- or L-configured CH2CONHR??, D- or L-configured CH2CH2CONHR??; wherein R1 is selected from hydrogen, chlorine, methoxy, methyl, trifluoromethyl, dimethoxy, methylenedioxy, and dichlorine, and R2 is selected from hydrogen, methoxy, ethoxy, isopropoxy, methyl, dimethoxy, and 2-methyl-4-methoxy, and wherein R?? is p-methoxyphenyl.

Abstract: The present invention is applicable to the field of the Internet of Things, and provides a method, a node, and a gateway for triggering networking. The method includes receiving, by a node, non-contact trigger induction; and adding the node and a gateway to a same network. The present invention provides a convenient trigger manner to add a node and a gateway to a same network, and ensures that the node is added to a correct network, thereby facilitating a user to perform an operation of triggering networking.

Abstract: Disclosed are an N-substituted pyrazolo[3,4-d]pyrimidine ketone compound of formula (I), and a preparation process and use thereof as a phosphodiesterase IX (PDEIX) inhibitor: wherein R? is selected from isopropyl, cyclopentyl, cyclohexyl, isobutyl, and o-chlorophenyl; when R??CH3, R represents benzyl; and when R??H, R is selected from 3-methylpyridine, 1-phenylethyl, 1-(4-chlorophenyl)ethyl, D- or L-configured CHCH3CONHR??, D- or L-configured CH2CONHR??, D- or L-configured CH2CH2CONHR??; wherein R1 is selected from hydrogen, chlorine, methoxy, methyl, trifluoromethyl, dimethoxy, methylenedioxy, and dichlorine, and R2 is selected from hydrogen, methoxy, ethoxy, isopropoxy, methyl, dimethoxy, and 2-methyl-4-methoxy, and wherein R?? is p-methoxyphenyl.

Abstract: The present invention discloses a traffic control method and a traffic control apparatus. The traffic control method comprising the steps of collecting key performance indexes of a system; and determining whether to limit requests entering into the system based on the collected key performance Indexes of the system, and it is determined that the requests entering into the system will be limited when a certain collected key performance Index of the system is inferior to a first threshold for a period of time, According to the invention, traffic control may be effectively, practically and flexibly provided to a system.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.